Arch Therapeutics, Inc.
Ticker: ARTH
Market Data:
Stock Ticker: ARTH
Web Site: http://bit.ly/-Web-Site
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch’s flagship development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
ARTH’s Flagship product AC5™ stops bleeding promptly, even in the presence of blood thinners based on animal data to date. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.
Reasons to Consider ARTH:
- Potential high margin (biopharma) differentiated product entering large growing market (2015) with lower (device) capital requirements
- Growing $5B market needs better solutions for bleeding & leaking
- First Planned Product – Hemostasis during surgery (2015) with initial launch in Europe.
- Ideal Planned Product Profile -Medical Device, rapid acting, safe, simple
- Unique Solution – MIT-licensed technology assembles into barrier on wound 2014
- Recent Data – Animal studies support efficacy in presence of “blood thinners”
- Activities – Scale-up, biocompatibility, initiate first human trial in coming months
- Significant R&D funding opportunity in Ireland – negotiating agreements
- Large potential in surgery, trauma, wound care, military
Arch Therapeutics, Inc.
Ticker: ARTH
Media Contact
Company Name: PublicWire
Contact Person: Dave Donlin
Email: Send Email
Phone: 4074906635
Address:5850 TG Lee Blvd, Suite 300
City: Orlando
State: FL
Country: United States
Website: http://publicwire.com
Source: www.abnewswire.com
